Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2012

View Archived Issues

First patient dosed in phase II ELND-005 trial in bipolar disorder

Pathophysiological changes occur years before Alzheimer's disease symptoms develop

Allergan designs new FPRL1 ligands

Novel peptides for skin disorders disclosed by OrganoBalance

Takeda presents novel inhibitors of ACC2

Washington University presents new PET/SPECT imaging agents

Novel bacterial efflux pump inhibitors patented by Rempex Pharmaceuticals

Amgen presents novel beta-secretase inhibitors

Astellas Pharma discloses new 5-HT5A receptor ligands

AZD-9708 may have potential for obstructive airways diseases

Abilify filed in Japan as adjunctive treatment for major depressive disorder

CB2 receptor agonist proves useful for the treatment of erectile dysfunction

Mechanism of action of epelsiban besilate further elucidated

NeuroSearch transfers Janssen research collaboration agreement to Aniona

Phase I/II data suggest transrectal administration of PRX-302 is well tolerated in BPH

Janssen-Cilag submits European MAA for bedaquiline

VLST licenses CP-870893 from Pfizer

Oxis Turbuhaler launched in Japan

Bristol-Myers Squibb profiles novel MCH1 receptor antagonist

Novo Nordisk gives update on approval of insulin degludec in Japan

TB Alliance advances development of antitubercular nitroimidazoles

Companies seek additional indication approval for proton pump inhibitors

Gilead presents data on GS-9669 for HCV infection

Quest Diagnostics launches molecular cervical cancer test

NanoViricides reports findings from animal study of oral FluCide program

FDA approves Xtandi for metastatic castration-resistant prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...